Market Overview

NeuroMetrix Closes 510(k) Clearance Process for SENSUS

Related NURO
Morning Market Movers
Benzinga's Top #PreMarket Gainers

NeuroMetrix, Inc. (Nasdaq: NURO), www.neurometrix.com, a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, reported that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the disposable electrode that is used in conjunction with its SENSUS device. This regulatory determination by the FDA gives NeuroMetrix clearance to market the SENSUS Pain Management System in the U.S. market.

The SENSUS device is a transcutaneous electrical nerve stimulator intended for the symptomatic relief and management of chronic intractable pain in the lower leg and foot. It is a light weight, low profile device worn on the upper calf and activated by the press of a single button. It can be placed in seconds and may be worn under clothing.

Posted-In: News FDA

 

Related Articles (NURO)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters